Baxalta: A Rare Undervalued Biopharmaceutical Company

Baxalta (BXLT) was created on July 1st 2015 when Baxter (BAX) spun-off its biopharmaceutical division. Baxalta may be new, but it is no start-up company.  Baxalta has estimated annual revenues of around $6 billion, and 16,000 employees. Around 50% of Baxalta’s sales come from the United States, with the other 50% from international markets. The … Read more